[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Context Therapeutics Inc (CNTX)

Context Therapeutics Inc (CNTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 238,885
  • Shares Outstanding, K 91,879
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,120 K
  • EBIT $ -44 M
  • EBITDA $ -43 M
  • 60-Month Beta 1.57
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 4
  • High Estimate $-0.04
  • Low Estimate $-0.10
  • Prior Year $-0.09
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.09 +24.70%
on 05/19/26
2.62 -0.76%
on 05/22/26
+0.19 (+7.88%)
since 04/22/26
3-Month
2.08 +25.00%
on 03/02/26
3.62 -28.18%
on 03/16/26
+0.36 (+16.07%)
since 02/20/26
52-Week
0.49 +430.61%
on 05/30/25
3.62 -28.18%
on 03/16/26
+1.89 (+268.59%)
since 05/22/25

Most Recent Stories

More News
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 ...

CNTX : 2.60 (+8.33%)
BCAB : 3.69 (+2.07%)
Context Therapeutics Reports First Quarter 2026 Operating and Financial Results

Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for...

CNTX : 2.60 (+8.33%)
Neogen® Corporation Announces Appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary

Neogen Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary. ...

CNTX : 2.60 (+8.33%)
NEOG : 8.90 (+0.45%)
Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April...

CNTX : 2.60 (+8.33%)
Context Therapeutics Reports Full Year 2025 Operating and Financial Results

Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents...

CNTX : 2.60 (+8.33%)
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”)...

CNTX : 2.60 (+8.33%)
Context Therapeutics to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific...

CNTX : 2.60 (+8.33%)
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific...

CNTX : 2.60 (+8.33%)
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”)...

CNTX : 2.60 (+8.33%)
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash...

CNTX : 2.60 (+8.33%)

Business Summary

Context Therapeutics Inc. is a women's oncology company developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. Context Therapeutics Inc. is headquartered in Philadelphia, PA.

See More

Key Turning Points

3rd Resistance Point 2.85
2nd Resistance Point 2.73
1st Resistance Point 2.67
Last Price 2.60
1st Support Level 2.49
2nd Support Level 2.37
3rd Support Level 2.31

See More

52-Week High 3.62
Last Price 2.60
Fibonacci 61.8% 2.42
Fibonacci 50% 2.05
Fibonacci 38.2% 1.69
52-Week Low 0.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.